Introduction to Pharmacology Flashcards
(98 cards)
1
Q
Pharmacology
A
- The study of the effects of drugs on the function of
living systems
2
Q
Drug
A
- A chemical substance of known structure, other
than a nutrient or an essential dietary ingredient,
which, when administered to a living organism,
produces a biological effect
3
Q
510 BC
* Pythagoras
(2)
A
— fava bean ingestion was dangerous for some
* now known to be G6PDH deficient individuals
— Pythagoras would not eat beans
4
Q
SKIPPED
De Materia Medica (“Concerning
Medical Substances”)
(3)
A
- 1st Century AD
- Pedanius Dioscorides (90-40 AD)
— Greek botantist/pharmacologist/physician
— served in Nero’s army as a botantist - Five volume collection on medicinal
plants
5
Q
SKIPPED
Shennong Bencao Jing (“The Divine
Farmer’s Herb-Root Classic”)
(2)
A
- 1st Century AD
- Han Dynasty
6
Q
SKIPPED
Medieval Times
* Robert Boyle (1627-1691)
(3)
A
— Scientific foundations of chemistry beginning to
be established in 17th century
— Surprisingly content with lack of scientific
approach to therapeutics
— A Collection of Choice Remedies, 1692 (Robert
Boyle)
7
Q
- Boyle’s Law:
A
inverse proportionality between
pressure and volume of gas
8
Q
SKIPPED
Colchicine
* history
(2)
A
— history dating back to Dioscorides
— isolated from the Autumn Crocus plant in
1820
9
Q
SKIPPED
Benjamin Franklin –
A
world traveler and gout
sufferer; introduced colchicine to the U.S.
10
Q
Paul Ehrlich (1854-1915)
* Modern Chemotherapy
(5)
A
— German physician-scientist
— How to differentiate healthy
tissue from invading pathogen?
— Staining techniques led
eventually to Gram staining
— arsphenamine (Salvasan)
— 1908 Nobel Prize
* contributions to immunology
11
Q
— arsphenamine (Salvasan)
* Treatment of
A
syphilis
12
Q
SKIPPED
Gerhard Domagk (1895-1964)
* German pathologist (Bayer)
* 1908—
A
synthesis of azo dyes (German patents)
13
Q
SKIPPED
Gerhard Domagk (1895-1964)
* German pathologist (Bayer)
* 1932—
A
Klarer & Mietzsch* patent for azo dyes containing sulfonamide group
— Domagk studied synthetic azo dyes for action against Streptococci and Staphylococci
14
Q
SKIPPED
Gerhard Domagk (1895-1964)
* German pathologist (Bayer)
* 1933—
A
Prontosil (a red dye with the active metabolite = sulfanilamide) given to 10 month old infant with Staphylococcus septicemia* dramatic cure, but little credit given
— Domagk treats his own daughter with prontosil* dramatic cure, but he doesn’t tell anyone until later
15
Q
SKIPPED
Gerhard Domagk (1895-1964)
* German pathologist (Bayer)
* 1939—
A
Nobel Prize awarded to Domagk
16
Q
SKIPPED
1928: Alexander Fleming
(2)
A
- St. Mary’s in London
- Staphylococcus cultures contaminated with mold
17
Q
SKIPPED
1940: Oxford University
(1)
A
- Crude mold extract administered to Strep.-infected mice
18
Q
SKIPPED
1941: Clinical Trial
(4)
A
- Severely ill with Staphylococcus or Streptococcus infections
- 100L of broth required for 1 patient (24 hr regimen)
- Crude drug recovered in urine
- “remarkable substance grown in bedpans and purified through the Oxford police force”
19
Q
SKIPPED
Mold identified as Penicillium notatum
A
1943: U.S. Surgeon General
* allowed trials in military forces
First marketable penicillin
* several dollars/100,000 Units
1950s-1970s: Research
* discovery of penicillin began world wide search
Present:
* 100,000 Units of penicillin V potassium costs several cents notatum
20
Q
SKIPPED
1930’s to 2016
A
- U.S. Food & Drug Administration (FDA) created in
1938 - Over 1,500 “drugs” have been reviewed and
approved by the FDA - Many drugs in wide use prior to FDA
— aspirin, colchicine, morphine, etc - Kinch et al
— Drug Discov Today. 2014 Aug;19(8):1033-9 - On average, 25-30 New Molecular Entities (NME)
approved by FDA every year - Over 500 drugs approved since 1990
21
Q
- Basic & Clinical Pharmacology
A
— Pharmacokinetics & Pharmacodynamics (PKPD)
22
Q
- Organ System Pharmacology
(5)
A
— Cardiovascular pharmacology
— Immunopharmacology
— Neuropharmacology
— Gastrointestinal Pharmacology
— Respiratory Pharmacology
23
Q
Pharmacology & “Sub-Disciplines”
(5)
A
Pharmacology
Pharmacogenetics
Pharmacogenomics
Pharmacoepidemiology
Pharmacoeconomics
24
Q
- Basic & Clinical Pharmacology
(3)
A
— Pharmacokinetics & Pharmacodynamics (PKPD)
— Pharmacokinetics
— Pharmacodynamics
25
— Pharmacokinetics
(4)
* Absorption
* Distribution
* Metabolism
* Excretion
26
— Pharmacodynamics
(3)
* Drug-receptor interactions
* Signal transduction
* Drug effects
27
Pharmacogenetics
(2)
* the metabolic fate of a drug based on individual genetic differences
* study of genetic influences on the responses to drugs
28
Pharmacogenomics
(2)
* the genetic basis of a drug’s absorption, distribution, metabolism, excretion, and receptor-target affinity
— the genetic basis of a drug’s pharmacokinetics and pharmacodynamics
— an extension of pharmacogenetics
* use of genetic information to guide the choice of drug therapy on an individual basis
29
Pharmacoepidemiology
(3)
* The study of drug effects at the population
level
* Concerned with variability of drug effects
between individuals in a population and
between populations
* Made possible with “Big Data” sets
30
Pharmacoeconomics
(2)
* The study of cost and benefits/detriments
of drugs used clinically
* Made possible with “Big Data” sets
31
U.S. Food & Drug Administration (FDA)
— administrative body that oversees drug
evaluation process
32
* FDA grants approval for marketing new
drug products
* FDA approval for marketing
(2)
— evidence of safety and efficacy
— “safe” does not mean complete absence of risk
33
FDA and USDA
— FDA shares responsibility with USDA for food
safety
34
SKIPPED
* Pure Food and Drug Act of 1906
(1)
— prohibited mislabeling
35
SKIPPED
* Food, Drug, and Cosmetic Act of 1938
(3)
— required that new drugs be safe as well as pure
— did not require efficacy
— required enforcement by FDA
36
SKIPPED
* Durham-Humphrey Act of 1952
(1)
— Vested in the FDA power to determine which products could be sold without Rx
37
* Dietary Supplement Health and Education Act (1994)
(2)
— prohibited full FDA review of supplements and botanicals as drugs
— established labeling requirements for dietary supplements
38
SKIPPED
* FDA Safety and Innovation Act of 2012
(1)
— established new accelerated process for “breakthrough therapy”, “priority review”, and “fast-track” procedures
39
“Drug” as defined by FDA
* A substance recognized by
* A substance intended for use in the
* A substance (other than food) intended to affect the
* A substance intended for use as a
* Biological products are included within this definition
and are generally covered by the same laws and
regulations, but differences exist regarding their
an official pharmacopoeia or formulary
diagnosis, cure, mitigation, treatment, or prevention of disease
structure or any function of the body
component of a medicine but not a device or a component, part or
accessory of a device
manufacturing processes (chemical process versus
biological process.)
40
“Generic Drug” as defined by FDA
* A generic drug is the same as a brand name drug in
* Before approving a generic drug product, FDA requires many
* The FDA bases evaluations of
* By law, a generic drug product must contain the identical
amounts of the same --- as the brand name
product
* Drug products evaluated as "therapeutically equivalent" can
be expected to have
dosage, safety, strength, how it is taken, quality, performance, and
intended use
rigorous tests and procedures to assure that the generic drug can be substituted for the brand name drug
substitutability, or therapeutic equivalence of generic drugs on scientific evaluations
active ingredient(s)
equal effect and no difference when substituted for the brand name product
41
Paul Ehrlich (1854-1915)
* Modern Chemotherapy
— Drug actions not result of magical
— Drug action explained by
— “A drug will not work unless it is
---”
— Must develop a “---”
“vital forces”
conventional chemical
interactions between drugs and
tissues
bound
Magic Bullet
42
Protein Targets for Drug Binding
(5)
* Receptors
* Enzymes
* Carrier Molecules (Transporters)
* Ion Channels
* Specific Circulating Plasma Proteins
43
Nucleic Acid Targets for Drug Binding
* RNA & DNA
44
Other Targets
* Ion Chelators
45
Receptors
* Protein molecule which function to
recognize and respond to
endogenous chemical signals
— protein molecules which function to
recognize specific endogenous ligands
— may also recognize/bind xenobiotics
46
Receptors
* Classified based on
ligands
— increasing focus on developing new
classification system based on
genomics
47
Receptors (e.g. G-Protein Coupled)
* Autonomic Nervous System
(2)
— Adrenergic Receptors
* a1, a2, b1, b2, b3
— Cholinergic
* muscarinic (M)
48
Receptors (e.g. G-Protein Coupled)
* Vascular System
(4)
— angiotensin II receptors (AT1, AT2)
— endothelin receptors (ETA, ETB)
— prostaglandin receptors (DP, EP, FP, IP, TP)
— histamine receptors (H1, H2, H3)
49
Receptors (e.g. Nuclear)
* Steroid Receptors
(6)
— Estrogen Receptor (ER)
* ERa, ERb
— Androgen Receptor
— Glucocorticoid Receptor (cortisol)
— Mineralocorticoid Receptor (aldosterone)
— Retinoid X Receptor (RXR)
— Constitutive Androstane Receptor (CAR)
50
Drug Specificity
* For a drug to be useful:
(2)
— must act selectively on particular cells and
tissues
— must show a high degree of binding site
specificity
51
For a protein to function as a receptor:
(2)
— generally shows a high degree of ligand
specificity
— bind only molecules of certain physico-
chemical properties
* size, shape, charge, lipophilicity, etc
52
Angiotensin II
* Selectively activates angiotensin II
receptors in vascular smooth muscle
to cause contraction
— does not affect smooth muscle in the
gastrointestinal tract, genitourinary
tract, or uterus
53
Angiotensin II receptors selectively
bind angiotensin II
— do not bind angiotensinogen (precursor
to AT-II) or angiotensin IV (AT-II
metabolite with 1 aa removed, Phe)
54
Receptor “Binding” or “Bonding”
* Electrostatic (most common)
— weaker:
— stronger:
hydrogen bonding and van der Waals forces (dipoles)
ionic bonding
55
Hydrophobic (less common)
— weak associations of hydrophobic compounds with hydrophobic domains of receptors
56
Covalent (relatively rare)
(3)
— permanent, lasting bonding
— aspirin and cyclooxygenase
— omeprazole and proton pump
57
Physico-Chemical Properties of
Drugs
* size
— molecular weight ranging from 7 to
hundreds of thousands
Li+: MW = 7
Alirocumab: MW ~ 146,000
58
Lipophilicity
(4)
— more soluble in oil than water
* i.e. more soluble in fat than blood
— steroids
— readily diffuse across membranes
— more likely to by metabolized by gut and liver
59
Hydrophilic
(4)
— more soluble in water than oil
* i.e. more soluble in blood than fat
— small molecules, weak acids/bases
* ionized at physiologic pH (7.4)
— not as easy to diffuse across plasma membranes
— more likely to be excreted unchanged by kidney
60
Physico-Chemical Properties of
Drugs
* ionic charge
— weak acids (e.g. aspirin, pKa 3.5)
* pKa is the pH at which the concentrations of
ionized and unionized species are equal
61
Physico-Chemical Properties of Drugs
* chirality (stereoisomerism)
(4)
— enantiomers: 1 pair for each chiral carbon
— most drugs used as “racemic” mixtures
— carvedilol: a1, b1, b2 adrenergic receptor antagonist used to treat heart failure
— sometimes only one stereoisomer is active and the others produce adverse effects
62
R(+) Carvedilol:
blocks a adrenergic receptors
63
S(-) Carvedilol:
blocks b adrenergic receptors
64
R,S(+) Carvedilol:
blocks a, b adrenergic receptors
65
Affinity
(3)
— tendency of a drug to bind to the receptor
— dissociation constant (Kd) = concentration required for 50% saturation of available receptors
— inversely proportional to affinity
* higher the Kd (nM), lower the affinity
66
Efficacy
(2)
— tendency of a drug to activate the receptor once bound
— generally expressed as dose-response curves or concentration-effect curves
67
* highly effective (potent) drugs generally have high
affinity
68
Agonist
(3)
— posses significant efficacy
— full agonist = elicits maximal response
— partial agonist = elicits partial response, even when 100% of receptors are occupied
69
Antagonist efficacy
— possess zero efficacy
70
Allosteric Agonists and Antagonists
(2)
— bind to the same receptor, but do not prevent binding of the agonist
— can may enhance or inhibit the action of agonists
71
Hyperbolic Relation
Model of Receptor Actions
(3)
* Inactive (Ri) and Active (Ra) Receptors
* Cells express many thousands of receptors
* Agonists (D) have high affinity for activated state and stablize it
72
Cells express many thousands of receptors
(2)
— absent any agonist, some would be in activated (Ra) state (constitutively active), but most in Ri state
— minimal effect produced
73
Agonists (D) have high affinity for activated state and stablize it
(2)
— large percentage of total receptor pool resides in Ra-D state
— large effect is produced
74
Full Agonist
(3)
— high affinity for Ra and stabilize Ra on binding
— shift nearly entire pool of receptors from Ri to Ra-D (Ra bound to drug)
— maximal effect is produced
75
Partial Agonist
(4)
— do not stablize Ra as effectively
— significant fraction stays in Ri-D pool
— only partially effective no matter how high concentration
— some can act as agonist (if no full agonist is present) or antagonist (if if full agonist is present)
* e.g. pindolol, b-adrenergic receptor antagonist when epinephrine is present; agonist when absent (“intrinsic sympathomimetic activity”)
76
Antagonist
(3)
— Ra-D and Ri-D stay in same relative amounts as in the absence of any drug
— no change in effect measured
— block effects of agonist (neutral antagonist)
77
Inverse Agonist
(3)
— higher affinity for Ri than for Ra
— stabilize Ri on binding
— reduces any constitutive activity of receptor thus producing opposite effects as a conventional agonist
* e.g. g-aminobutyric acid (GABA) receptors; diazepam agonist, flumazenil antagonist, experimental compounds act as inverse agonist
78
SKIPPED
In Vitro (Cells or Tissue Homogenates)
(2)
— Mass Action Law
— Drug agonists act by binding to (“occupying”) a distinct receptor
79
* B =
drug bound to receptors at given concentration (C)
— As “dose” increases, binding increment diminishes
80
* Bmax =
point at which at which all receptors are bound
81
* Kd =
equilibrium dissociation constant or concentration
of drug where 50% of receptors are bound
— low Kd = high binding affinity and vice versa
82
Concentration-Effect (Dose-Response)
* In Vitro/In Vivo (Cells vs. Animals or Patients)
Hyperbolic Relation
— effect/response of low concentrations/doses of a drug usually
increases in direct proportion to concentration/dose
83
* E =
effect observed at given concentration (C)
— As “dose” increases, the effect/response increment diminishes
84
* Emax =
point at which at which no further
effect/response is achieved as “dose” increases further
85
* EC50 =
concentration of drug that produces 50% of
maximal effect/response
86
Model of Receptor Actions
* Antagonist
(3)
— Ra-D and Ri-D stay in same relative
amounts as in the absence of any drug
— no change in effect measured
— block effects of agonist (neutral
antagonist)
87
Model of Receptor Actions
* Competitive Antagonist
(4)
— bind to same site on receptor as agonist
— compete with agonist for binding
— with fixed agonist concentration, progressive increases in antagonist will progressively decrease effect up to completely abolishing it
— increasing agonist concentration can overcome competitive antagonist
88
Noncompetitive Antagonist
(3)
— often bind covalently and irreversibly
— often allosteric inhibition but can be same binding site as agonist
— increasing agonist concentration may not overcome noncompetitive antagonist
89
Chemical Antagonist
— for example: ionic interaction between positively charged protamine and negatively charged heparin
* protamine antagonizes heparin
90
Physiologic Antagonist
— for example: different regulatory pathways mediated by different receptors resulting in opposing actions
* anticholinergic atropine can physiologically antagonize effects of b-blockers on heart rate
91
Pharmacokinetic Antagonist
— one drug increases the metabolism of the other
* rifampin increases metabolism of many drugs
92
Termination of Drug-Receptor Actions
(4)
* Dissociation of drug from receptor
* Dissociation of drug from receptor but effects continue for some time
* Covalently bound drugs require destruction of the drug-receptor complex and synthesis of new receptors
* Desensitization
93
* Dissociation of drug from receptor but effects continue for some time
— downstream activation of effectors
* e.g. kinase phosphorylation of downstream proteins
— activated effectors have to be deactivated
* e.g. phosphatase dephosphorylation of downstream proteins
94
SKIPPED
* Covalently bound drugs require --- of the drug-receptor complex and synthesis of new receptors
destruction
— platelets and aspirin; omeprazole and proton pump
95
SKIPPED
Desensitization (a.k.a. Tachyphylaxis)
— change in receptors
* phosphorylation of receptor
— translocation of receptors
* b-adrenergic receptor internalization
— exhaustion of mediators
* neurotransmitter depletion
— increased drug metabolism
— physiologic adaptation
* blood pressure lowering from a diuretic
— active extrusion of drug from cell
* multi-drug resistance (P-glycoprotein)
96
Rapid Responses (seconds to minutes)
(2)
—b-adrenergic receptor activation
— nicotinic-acetylcholine receptor
activation in nerve synapse
97
Intermediate Responses (minutes to
hours)
— receptor desensitization
98
Delayed Responses (hours to days)
— steroid-induced increase in gene
expression
